Catabasis Pharmaceuticals, Inc. – NASDAQ:CATB

Founder-led company

Catabasis Pharmaceuticals stock price today

$8.54

Catabasis Pharmaceuticals stock price yearly change

-59.79%
year

Catabasis Pharmaceuticals key metrics

Market Cap
 234.86M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Catabasis Pharmaceuticals stock price history

Catabasis Pharmaceuticals stock forecast

Catabasis Pharmaceuticals financial statements

Catabasis Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Catabasis Pharmaceuticals
Employees

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): Employee count
Aug 2023 20
Sep 2023 20
Oct 2023 20
Nov 2023 20
Dec 2023 20
Jan 2024 20
Feb 2024 20
Mar 2024 20
Apr 2024 20
May 2024 20
Jun 2024 20
Jul 2024 20
Dec 2024 20

Catabasis Pharmaceuticals other data

Catabasis Pharmaceuticals
Insider Trading

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): Insider trades (number of shares)
Period Buy Sel
Jun 2015 1850134 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
GEORGE JEAN director
 Common Stock 258,776 $12 $3,105,312
Purchase
LAUFER RON director, 10 percent owner
 Common Stock 223,439 $12 $2,681,268
Purchase
CLARUS LIFESCIENCES II, L.P. 10 percent owner
 Common Stock 376,695 $12 $4,520,340
Purchase
SVLSF V, LLC 10 percent owner
 Common Stock 391,090 $12 $4,693,080
Purchase
MEDIMMUNE VENTURES, INC. 10 percent owner
 Common Stock 223,439 $12 $2,681,268
Purchase
GALAKATOS NICHOLAS director
 Common Stock 376,695 $12 $4,520,340
CATB insider trading transactions

Catabasis Pharmaceuticals
Patents

Patent
Application
Filling date: 2 Jul 2020 Issue date: 10 Jun 2021
Application
Filling date: 5 Nov 2018 Issue date: 28 Jan 2021
Application
Filling date: 14 Mar 2019 Issue date: 13 Feb 2020
Application
Filling date: 8 Apr 2019 Issue date: 6 Feb 2020
CATB patents

Catabasis Pharmaceuticals
Earnings Call Transcripts

Quarter Transcript
Q4 2019 10 Mar 2020 Q4 2019 Earnings Call Transcript
Q3 2019 7 Nov 2019 Q3 2019 Earnings Call Transcript
Q2 2019 8 Aug 2019 Q2 2019 Earnings Call Transcript
Q1 2019 14 May 2019 Q1 2019 Earnings Call Transcript
CATB earnings call transcripts

Frequently Asked Questions (FAQ)

  • What's the price of Catabasis Pharmaceuticals stock today?

    One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $8.54.

  • When is Catabasis Pharmaceuticals's next earnings date?

    Unfortunately, Catabasis Pharmaceuticals's (CATB) next earnings date is currently unknown.

  • Does Catabasis Pharmaceuticals pay dividends?

    No, Catabasis Pharmaceuticals does not pay dividends.

  • How much money does Catabasis Pharmaceuticals make?

    Catabasis Pharmaceuticals has a market capitalization of 234.86M.

  • What is Catabasis Pharmaceuticals's stock symbol?

    Catabasis Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CATB".

  • What is Catabasis Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Catabasis Pharmaceuticals?

    Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Catabasis Pharmaceuticals's key executives?

    Catabasis Pharmaceuticals's management team includes the following people:

    • Ms. Jill C. Milne Co-Founder, Chief Executive Officer, Pres & Director(age: 57, pay: $734,540)
    • Dr. Joanne M. Donovan Chief Medical Officer & Senior Vice President of Clinical Devel.(age: 68, pay: $594,410)
    • Dr. Andrew J. Nichols Chief Scientific Officer(age: 64, pay: $512,640)
    • Mr. Noah Clauser CPA Chief Financial Officer
    • Ms. Andrea L. Matthews Senior Vice President of Corporation Affairs
    • Mr. Andrew A. Komjathy Chief Commercial Officer
    • Mr. Benjamin S. Harshbarger J.D. Senior Vice President & Gen. Counsel

  • Is Catabasis Pharmaceuticals founder-led company?

    Yes, Catabasis Pharmaceuticals is a company led by its founder Ms. Jill C. Milne.

  • How many employees does Catabasis Pharmaceuticals have?

    As Dec 2024, Catabasis Pharmaceuticals employs 20 workers.

  • When Catabasis Pharmaceuticals went public?

    Catabasis Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 25 Jun 2015.

  • What is Catabasis Pharmaceuticals's official website?

    The official website for Catabasis Pharmaceuticals is catabasis.com.

  • Where are Catabasis Pharmaceuticals's headquarters?

    Catabasis Pharmaceuticals is headquartered at 100 High Street, 28th Floor, Boston, MASSACHUSETTS.

  • How can i contact Catabasis Pharmaceuticals?

    Catabasis Pharmaceuticals's mailing address is 100 High Street, 28th Floor, Boston, MASSACHUSETTS and company can be reached via phone at +1 617 349 1971.

Catabasis Pharmaceuticals company profile:

Catabasis Pharmaceuticals, Inc.

catabasis.com
Exchange:

NASDAQ

Full time employees:

20

Industry:

Biotechnology

Sector:

Healthcare

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

+1 617 349 1971
100 High Street, 28th Floor
Boston, MASSACHUSETTS 02139

CIK: 0001454789
ISIN: US14875P2065
CUSIP: 14875P206